Security National Bank Grows Holdings in Boston Scientific Corporation $BSX

Key Points

• Security National Bank increased its Boston Scientific holdings by 52.3% in the second quarter, owning 74,682 shares worth approximately $3.19 million. Institutional investors collectively own 89.07% of the company.
• Boston Scientific beat quarterly expectations with $0.86 EPS and $5.44 billion in revenue, while revenue rose 7.5% year over year. The company provided third-quarter EPS guidance of $0.80–$0.82 and full-year guidance of $3.28–$3.32.
• The company authorized a $5 billion share-repurchase plan, and insiders—including CEO Michael Mahoney—purchased roughly $9.94 million of shares over the past 90 days. Analysts maintain a “Moderate Buy” consensus with an average price target of $71.62.

Security National Bank raised its holdings in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 52.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 74,682 shares of the medical equipment provider's stock after purchasing an additional 25,654 shares during the quarter. Security National Bank's holdings in Boston Scientific were worth $3,187,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in BSX. Vanguard Group Inc. lifted its holdings in Boston Scientific by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 139,685,997 shares of the medical equipment provider's stock valued at $13,319,060,000 after buying an additional 1,436,550 shares in the last quarter. State Street Corp grew its stake in Boston Scientific by 1.4% in the 4th quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider's stock worth $6,278,422,000 after acquiring an additional 920,495 shares in the last quarter. Capital World Investors increased its position in shares of Boston Scientific by 1.9% during the fourth quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider's stock worth $2,588,953,000 after acquiring an additional 502,627 shares during the period. Norges Bank bought a new stake in shares of Boston Scientific during the fourth quarter valued at approximately $2,199,395,000. Finally, Morgan Stanley boosted its holdings in shares of Boston Scientific by 10.8% in the fourth quarter. Morgan Stanley now owns 22,960,556 shares of the medical equipment provider's stock valued at $2,189,289,000 after purchasing an additional 2,246,308 shares during the period. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Price Performance

NYSE:BSX opened at $51.40 on Thursday. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. Boston Scientific Corporation has a 52 week low of $42.20 and a 52 week high of $109.50. The stock's 50-day moving average price is $45.94 and its 200-day moving average price is $59.69. The stock has a market capitalization of $74.49 billion, a PE ratio of 20.81, a price-to-earnings-growth ratio of 1.12 and a beta of 0.56.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The business had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. During the same quarter last year, the business earned $0.75 earnings per share. The company's revenue for the quarter was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, equities analysts expect that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific declared that its board has initiated a stock repurchase plan on Monday, May 18th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company's board of directors believes its stock is undervalued.

Insiders Place Their Bets

In other news, Director Edward J. Ludwig bought 5,000 shares of the business's stock in a transaction on Friday, July 31st. The shares were bought at an average price of $45.48 per share, with a total value of $227,400.00. Following the completion of the transaction, the director directly owned 30,359 shares in the company, valued at $1,380,727.32. This trade represents a 19.72% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Michael F. Mahoney bought 186,240 shares of the business's stock in a transaction that occurred on Monday, August 3rd. The shares were acquired at an average cost of $48.33 per share, for a total transaction of $9,000,979.20. Following the completion of the purchase, the chief executive officer owned 1,590,024 shares in the company, valued at $76,845,859.92. This trade represents a 13.27% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders have purchased 204,322 shares of company stock valued at $9,939,221. 0.34% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research analysts have commented on the company. Argus restated a "hold" rating on shares of Boston Scientific in a report on Friday, July 31st. Barclays lowered their target price on Boston Scientific from $96.00 to $89.00 and set an "overweight" rating for the company in a report on Thursday, May 28th. Royal Bank Of Canada dropped their price target on Boston Scientific from $85.00 to $70.00 and set an "outperform" rating on the stock in a research report on Thursday, July 30th. Evercore set a $65.00 price objective on Boston Scientific in a report on Monday, July 6th. Finally, Mizuho lowered their price objective on shares of Boston Scientific from $90.00 to $70.00 and set an "outperform" rating for the company in a research note on Wednesday, July 15th. Twenty-four research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $71.62.

Boston Scientific Company Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source